Indexed keywords
BEVACIZUMAB;
PEGAPTANIB;
RANIBIZUMAB;
VERTEPORFIN;
MONOCLONAL ANTIBODY;
ANGIOGENESIS;
BLEEDING;
CATARACT;
CENTRAL SCOTOMA;
CLINICAL TRIAL;
CONJUNCTIVAL HEMORRHAGE;
DRUG APPROVAL;
DRUG COST;
DRUG EFFICACY;
DRUG ELIMINATION;
DRUG FORMULATION;
DRUG HALF LIFE;
DRUG MECHANISM;
DRUG SAFETY;
ENDOPHTHALMITIS;
EYE PAIN;
HEART INFARCTION;
HUMAN;
INTRAOCULAR PRESSURE;
PHOTODYNAMIC THERAPY;
RECOMMENDED DRUG DOSE;
RETINA DETACHMENT;
RETINA MACULA AGE RELATED DEGENERATION;
RETINA MACULA DEGENERATION;
RETINA TEAR;
SHORT SURVEY;
SIDE EFFECT;
STROKE;
SUBRETINAL NEOVASCULARIZATION;
THROMBOEMBOLISM;
VISUAL ACUITY;
VITREOUS FLOATERS;
PATHOPHYSIOLOGY;
REVIEW;
ANTIBODIES, MONOCLONAL;
HUMANS;
MACULAR DEGENERATION;
1
43149091789
Two new drugs for colon cancer. Med Lett Drugs Ther 2004; 46:46.
Two new drugs for colon cancer. Med Lett Drugs Ther 2004; 46:46.
2
33749440219
Age-related macular degeneration
PT de Jong. Age-related macular degeneration. N Engl J Med 2006; 355:1474.
(2006)
N Engl J Med , vol.355
, pp. 1474
de Jong, P.T.1
3
22344455695
Pegaptanib sodium (Macugen) for macular degeneration. Med Lett Drugs Ther 2005; 47:55.
Pegaptanib sodium (Macugen) for macular degeneration. Med Lett Drugs Ther 2005; 47:55.
4
33747891752
Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration
VISION Clinical Trial Group
VISION Clinical Trial Group. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 2006; 113:1508.
(2006)
Ophthalmology , vol.113
, pp. 1508
5
0034604916
Photodynamic therapy with verteporfin (Visudyne) for macular degeneration
Photodynamic therapy with verteporfin (Visudyne) for macular degeneration. Med Lett Drugs Ther 2000; 42:81.
(2000)
Med Lett Drugs Ther , vol.42
, pp. 81
6
33644502828
Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration
RL Avery et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006; 113:363.
(2006)
Ophthalmology , vol.113
, pp. 363
Avery, R.L.1
7
33745091547
Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration
RF Spaide et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006; 26:383.
(2006)
Retina , vol.26
, pp. 383
Spaide, R.F.1
8
33745418105
Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration
ZF Bashshur et al. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006; 142:1.
(2006)
Am J Ophthalmol , vol.142
, pp. 1
Bashshur, Z.F.1
9
33749445317
Ranibizumab for neovascular age-related macular degeneration
PJ Rosenfeld et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 335:1419.
(2006)
N Engl J Med , vol.335
, pp. 1419
Rosenfeld, P.J.1
10
33749451356
Ranibizumab versus verteporfin for neovascular age-related macular degeneration
DM Brown et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355:1432.
(2006)
N Engl J Med , vol.355
, pp. 1432
Brown, D.M.1
11
43149125292
Genentech press release June 2, 2006. Available at www.gene.com. Accessed October 12, 2006.
Genentech press release June 2, 2006. Available at www.gene.com. Accessed October 12, 2006.
12
33747782925
Ranibizumab: Phase III clinical trial results
PJ Rosenfeld et al. Ranibizumab: phase III clinical trial results. Ophthalmol Clin North Am 2006; 19:361.
(2006)
Ophthalmol Clin North Am , vol.19
, pp. 361
Rosenfeld, P.J.1
